• 1
    Chong C, Logothetis CJ, von Eschenbach A, Ayala A, Samuels M. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response. J Urol 1986; 136: 12213
  • 2
    Greist A, Einhorn LH, Williams SD, Donohue JP, Rowland RG. Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer. J Clin Oncol 1984; 2: 10257
  • 3
    Leibovitch I, Little JS Jr, Foster RS, Rowland RG, Bihrle R, Donohue JP. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol 1996; 155: 9524
  • 4
    Ondrus D, Hornak M, Breza J et al. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol 2001; 32: 6657
  • 5
    Snow BW, Rowland RG, Donohue JP, Einhorn LH, Williams SD. Review of delayed orchiectomy in patients with disseminated testis tumors. J Urol 1983; 129: 5223
  • 6
    Bart J, Groen HJ, van der Graaf WT, Hollema H et al. An oncological view on the blood-testis barrier. Lancet Oncol 2002; 3: 35763
  • 7
    Dave DS, Leppert JT, Rajfer J. Is the testis a chemo-privileged site? Is there a blood-testis barrier? Rev Urol 2007; 9: 2832
  • 8
    Kamps WA, Bokkerink JP, Hahlen K et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988–1991). Blood 1999; 94: 122636
  • 9
    Miniero R, Saracco P, Pastore G et al. Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: a 10-year follow-up study. Italian Association of Pediatric Hematology-Oncology (AIEOP). Med Pediatr Oncol 1995; 24: 716
  • 10
    Touroutoglou N, Dimopoulos MA, Younes A et al. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol 1995; 13: 13617
  • 11
    Simmonds PD, Mead GM, Lee AH, Theaker JM, Dewbury K, Smart CJ. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? Cancer 1995; 75: 101824
  • 12
    Christensen TB, Daugaard G, Geertsen PF, von der Maase H. Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 1998; 9: 65760
  • 13
    van Basten JP, Hoekstra HJ, van Driel MF, Sleijfer DT, Droste JH, Schraffordt Koops H. Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer. Ann Surg Oncol 1997; 4: 3428
  • 14
    Schlag P, Schreml W. Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay. Cancer Res 1982; 42: 40869
  • 15
    Spremulli EN, Dexter DL. Human tumor cell heterogeneity and metastasis. J Clin Oncol 1983; 1: 496509
  • 16
    Huddart RA, Gabe R, Cafferty F et al. A randomised phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN53643604). NCRI Cancer Conference 2011. 2011. Abstract number A71
  • 17
    Geldart TR, Simmonds PD, Mead GM. Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int 2002; 90: 4515
  • 18
    Jacobsen NE, Beck SD, Jacobson LE, Bihrle R, Einhorn LH, Foster RS. Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? J Urol 2010; 184: 94953
  • 19
    Steyerberg EW, Keizer HJ, Messemer JE et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group. Cancer 1997; 79: 34555
  • 20
    Holash JA, Harik SI, Perry G, Stewart PA. Barrier properties of testis microvessels. Proc Natl Acad Sci USA 1993; 90: 1106973
  • 21
    Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 2010; 333: 78896
  • 22
    Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698705
  • 23
    Cordon-Cardo C, O'Brien JP, Casals D et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 6958
  • 24
    Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 77358
  • 25
    van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst 1996; 88: 9949
  • 26
    Albers P, Weissbach L, Krege S et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 2004; 171: 18358
  • 27
    Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010; 28: 5316
  • 28
    Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003; 21: 33107
  • 29
    Motzer RJ, Amsterdam A, Prieto V et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998; 159: 1338
  • 30
    Spiess PE, Pisters LL, Liu P et al. Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol 2008; 26: 5959
  • 31
    Svatek RS, Spiess PE, Sundi D et al. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 2009; 115: 13107
  • 32
    De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 15: 10349
  • 33
    Puc HS, Heelan R, Mazumdar M et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996; 14: 45460
  • 34
    Schultz SM, Einhorn LH, Conces DJ Jr, Williams SD, Loehrer PJ. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989; 7: 1497503
  • 35
    Heidenreich A, Weissbach L, Holtl W et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001; 166: 21615